| Linagliptin , a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 22149370 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Introduction: Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. Areas covered: This paper reviews studies that evaluate the pharmacokinetics, pharmacodynamics and clinical efficacy and safety of linagliptin , a dipeptidyl peptidase-4 (DPP-4) inhibitor, recently approved in the US, Japan and Europe for the treatment of T2DM. Expert opinion: Oral linagliptin, 5 mg once daily, is an effective, well-tolerated DPP-4 inhibitor, suitable for use in a wide range of patients with T2DM. It is weight-neutral, without increasing the risk of hypoglycemia, and can be administered either alone or in combination with other diabetes treatments. It has a unique pharmacological profile within its class and, unlike other DPP-4 inhibitors, linagliptin does not require dose adjustment in patients with renal impairment. |
| | |
Authors:
|
Thomas Forst; Andreas Pfützner |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 13 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-12-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 101-10 Citation Subset: IM |
Affiliation:
|
Institute for Clinical Research and Development , Mainz , Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A review of gliptins in 2011.
Next Document: Istradefylline for the treatment of Parkinson's disease.